Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetophenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | HTR1A | P08908 | 4/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.71 |
| ▸ | HTR2A | P28223 | 4/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.71 |
| ▸ | HRH1 | P35367 | 4/20 | 0.71 |
| ▸ | DRD3 | P35462 | 4/20 | 0.71 |
| ▸ | HTR2B | P41595 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine SCHEMBL7623667 | 0.98 | LMNA (0.74) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Acetophenazine SCHEMBL28843774 | 0.94 | HTR1A (0.79) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Fluphenazine SCHEMBL565707 | 0.90 | LMNA (0.85) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Trifluoperazine SCHEMBL1590789 | 0.90 | RAD52 (0.84) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Trifluoperazine SCHEMBL1590788 | 0.90 | RAD52 (0.84) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Fluphenazine SCHEMBL565708 | 0.90 | LMNA (0.85) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Acetophenazine SCHEMBL123789 | 0.89 | HRH1 (0.89) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Acetophenazine SCHEMBL123792 | 0.89 | HRH1 (0.89) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Acetophenazine SCHEMBL1155759 | 0.89 | HRH1 (0.89) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 | |
| Acetophenazine SCHEMBL30903895 | 0.89 | HRH1 (0.89) | LMNAMAPTSMN1; SMN2MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10094836-B2 | SLCO1B3 genotype | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2018-10-09 | — | — | US | disclosed |
| EP-1943358-B1 | CYP1B1 GENOTYPE | US GOV HEALTH & HUMAN SERV (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2115173-B1 | SLCO1B3 GENOTYPE | US GOV HEALTH & HUMAN SERV (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100317726-A1 | SLCO1B3 GENOTYPE | Government of the United States of America, as rep resented by the Secretary Dept. of Health and Hum (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100280084-A1 | Cyp1B1 Genotype | Government of the US, as represented by the Secret ary, Department of Health and Human Services (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2115173-A2 | SLCO1B3 GENOTYPE | Government of the USA, as Represented by the Secretary, Department of Health and Human Services (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008112283-A2 | MICRORNA PROFILING OF ANDROGEN RESPONSIVENESS FOR PREDICTING THE APPROPRIATE PROSTATE CANCER TREATMENT | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008086002-A2 | SLCO1B3 GENOTYPE | GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1943358-A2 | CYP1B1 GENOTYPE | Government of the USA, as Represented by the Secretary, Department of Health and Human Services (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070072232-A1 | Identification of genetic components of drug response | VARIAGENICS, INC. A DELAWARE CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070031853-A1 | Gene sequence variations with utility in determining the treatment of neurological or psychiatric disease | VARIAGENICS, INC., A DELAWARE CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20040171056-A1 | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing | VARIAGENICS, INC., A DELAWARE CORPORATION | 2004-09-02 | — | — | US | disclosed |
| EP-1248832-A4 | IDENTIFICATION OF GENETIC COMPONENTS OF DRUG RESPONSE | VARIAGENICS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040082000-A1 | Identification of genetic components of drug response | VARIAGENICS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1248832-A1 | IDENTIFICATION OF GENETIC COMPONENTS OF DRUG RESPONSE | Variagenics, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1224322-A2 | GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | Variagenics, Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20020012921-A1 | Detecting phenotypesin cells; monitor cells and evaluate transmission pattern of phenotypes | VARIAGENICS, INC. | 2002-01-31 | — | — | US | disclosed |
| US-20010034023-A1 | Identifying and predicting genetic based inter-patient differences in response to drugs in order to achieve superior efficacy and saftey in selected patient population; pharmacokinetics and toxicology | VARIAGENICS, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001053460-A1 | IDENTIFICATION OF GENETIC COMPONENTS OF DRUG RESPONSE | VARIAGENICS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2000050639-A2 | GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | VARIAGENICS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171056-A1 | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing | GUSB, TSG101, DCLRE1B | DRD2 4655/4885LMNA 2424/4885MAPT 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.